• Enrollment in RCTs Not Detrimental to Preterm Infants

  • Communicating Parents’ Preferences, Goals in ADHD

  • Gender Bias in Growth Hormone Treatment for Height

  • 1
  • 2
  • 3

Welcome to Discovery to Innovation

Discovery to Innovation is a quarterly update of news, research findings, and game-changing developments at
The Childrenʼs Hospital of Philadelphia Research Institute.

load more hold SHIFT key to load all load all

The Children's Hospital of Philadelphia researchers have discovered two gene variants that raise the risk of the pediatric cancer neuroblastoma. The study, which draws on genome-wide association studies (GWAS) on DNA from thousands of subjects, broadens our understanding of how gene changes can make a child susceptible to this early childhood cancer and how those changes can cause a tumor to progress.

"We discovered common variants in the HACE1 and LIN28B genes that increase the risk of developing neuroblastoma. For LIN28B, these variants also appear to contribute to the tumor's progression once it forms," said first author Sharon J. Diskin, PhD, a pediatric cancer researcher at Children's Hospital. "HACE1 and LIN28B are both known cancer-related genes, but this is the first study to link them to neuroblastoma."

Affecting the peripheral nervous system, neuroblastoma usually appears as a solid tumor in the chest or abdomen. It accounts for 7 percent of all childhood cancers, and 10 to 15 percent of all childhood cancer deaths.

The study team performed a GWAS, comparing DNA from 2,800 neuroblastoma patients with that of nearly 7,500 healthy children. They found two common gene variants associated with neuroblastoma, both in the 6q16 region of chromosome 6. One variant is within the HACE1 gene, the other in the LIN28B gene. They exert opposite effects: HACE1 functions as a tumor suppressor gene, hindering cancer, while LIN28B is an oncogene, driving cancer development.

The current study showed that low expression of HACE1, a tumor suppressor gene, and high expression of LIN28B, an oncogene, correlated with worse patient survival. To further investigate the gene's role, the researchers used genetic tools to decrease LIN28B's activity, and showed that this inhibited the growth of neuroblastoma cells in culture.

"In addition to broadening our understanding of the heritable component of neuroblastoma susceptibility, we think this research may suggest new therapies," Dr. Diskin noted.

Read the full press release.

Links of Interest

  • CHOP Research Institute Website +

    The Children's Hospital of Philadelphia has a long and distinguished tradition of research that has spanned nearly a century. The Read More
  • CHOP Website +

    The Children's Hospital of Philadelphia (CHOP) is the nation's first hospital devoted exclusively to the care of children. Since our Read More
  • Bench to Bedside +

    Published monthly, Bench to Bedside enhances communication with investigators and research staff. Each issue includes news, announcements, awards, new employees Read More
  • CHOP Foundation Website +

    A Million Stories of Hope. Countless Reasons to Give Every story of hope at The Children’s Hospital of Philadelphia is Read More
  • 1